Passage Bio (NASDAQ:PASG) Director Athena Countouriotis acquired 10,000 shares of the business’s stock in a transaction on Tuesday, March 24th. The shares were purchased at an average price of $14.74 per share, for a total transaction of $147,400.00.
PASG stock traded up $0.38 on Thursday, reaching $15.12. The company’s stock had a trading volume of 2,236 shares, compared to its average volume of 640,102. Passage Bio has a 52 week low of $8.09 and a 52 week high of $23.25.
PASG has been the subject of several recent research reports. Cowen began coverage on Passage Bio in a report on Tuesday. They set an “outperform” rating for the company. JPMorgan Chase & Co. began coverage on Passage Bio in a report on Tuesday. They issued an “overweight” rating and a $25.00 price objective for the company. Chardan Capital began coverage on Passage Bio in a report on Wednesday. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Goldman Sachs Group began coverage on Passage Bio in a report on Tuesday. They issued a “buy” rating and a $27.00 price objective for the company.
Passage Bio, Inc, a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has a research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.